Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesClinical/Medical PolicyPrime Therapeutics CGM Prior Auth Coverage | OpenP…
    Ask Trek AI about this page
    CurrentPrime TherapeuticsPolicy N/A

    Continuous Glucose Monitor Prior Authorization with Quantity Limit Program Summary

    Customize your policy alerts

    Sign up for all prime_therapeutics policy alerts

    Know when prime_therapeutics releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and quantity limits for continuous glucose monitor receivers, sensors, and transmitters for commercial members. Coverage applies to specified Dexcom and FreeStyle Libre products when clinical criteria and applicable quantity-limit requirements are met.

    Policy Summary
    PayerPrime Therapeutics
    PolicyContinuous Glucose Monitor Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionSubmit clinical documentation supporting the qualifying diabetes diagnosis, age requirement, prerequisite therapy, and continuation history when applicable.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsPrior authorization approval duration
    90 daysContinuation therapy use period
    365 daysReceiver quantity limit
    30 daysDexcom G6/G7 sensor limit

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2 per 30/28 daysNewer sensor quantity limit
    3Qualifying diabetes types

    Coverage Criteria

    Initial or continuation therapy

    Covered when ONE of the following pathways is met.

    Continuation or initial therapy

    • Continuation therapy: The prescriber states that the patient has been treated with the requested agent within the past 90 days and is at risk if therapy is changed.Treatment with requested agent within past 90 days

      Starting on samples is not approvable.

    • Initial therapy

      • Qualifying diagnosis: The patient has type 1 diabetes, type 2 diabetes, or gestational diabetes.One diagnosis
      • Age requirement: The patient's age is within FDA labeling for the requested indication, or there is support for using the requested agent for the patient's age and indication.One option
      • Prerequisite-agent criterion: There is medication history of use within the past 90 days of one prerequisite agent, intolerance or hypersensitivity to one prerequisite agent, or an FDA-labeled contraindication to all prerequisite agents.One option

    Quantity-limit criteria

    The quantity limit will be approved when ONE of the following is met.

    Quantity-limit approval

    • Within program limit: The requested quantity does not exceed the program quantity limit.At or below applicable limit
    • No maximum FDA-labeled dose: The requested quantity exceeds the program limit, the requested agent does not have a maximum FDA-labeled dose for the requested indication, and there is support for therapy with a higher dose.No maximum FDA-labeled dose
    • Lower quantity of higher strength is not feasible: The requested quantity exceeds the program limit, the requested quantity does not exceed the maximum FDA-labeled dose, and there is support for why the quantity cannot be achieved with a lower quantity of a higher strength that remains within the program limit.

    Continuation therapy initiated only with samples is not approvable. For continuation approval, the prescriber must state that the patient has been treated with the requested agent within the past 90 days and is at risk if therapy is changed.

    Covered Products and Quantity Limits

    Targeted NDCsNDC
    086270Targeted NDC identifier shown for specified receiver, sensor, and transmitter products
    05303Targeted NDC identifier shown for Dexcom sensor products
    07901Targeted NDC identifier shown for specified newer sensor products
    575990 83500Targeted NDC identifier shown for specified newer sensor products
    575990 83501Targeted NDC identifier shown for specified newer sensor products
    575990 84400Targeted NDC identifier shown for specified newer sensor products
    84401Targeted NDC identifier shown for FreeStyle Libre sensor products
    575990 00101Targeted NDC identifier shown for FreeStyle Libre sensor products
    575990 80000Targeted NDC identifier shown for FreeStyle Libre sensor products
    Receiver Quantity Limit
    ProductsDexcom G6 receiver; Dexcom G7 receiver; FreeStyle Libre 14-day reader; FreeStyle Libre reader
    EquipmentReceiver
    Quantity-limit duration365 days
    Dexcom G6/G7 Sensor Quantity Limit
    ProductsDexcom G6 sensor; Dexcom G7 sensor
    EquipmentSensors
    Quantity-limit duration30 days

    Provider Requirements and Denial Risks

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for the listed continuous glucose monitor (CGM) target agents. Requests must satisfy the applicable clinical criteria and, when applicable, the quantity-limit criteria.

    • Dexcom G6
    • Dexcom G7
    • FreeStyle Libre
    • FreeStyle Libre 2
    • FreeStyle Libre 2 Plus
    • FreeStyle Libre 3
    • FreeStyle Libre 3 Plus
    Step Therapy

    Prerequisite Diabetes Therapy

    Document prerequisite diabetes therapy for the requested CGM. Coverage may be supported by recent use of one prerequisite agent, intolerance or hypersensitivity to one prerequisite agent, or an FDA-labeled contraindication to all prerequisite agents.

    Continuous Glucose Monitor Overview

    Continuous glucose monitors (CGMs) provide ongoing glucose measurements through a sensor and an associated receiver or transmitter. This policy addresses prior authorization for CGM receivers, sensors, and transmitters, including Dexcom and FreeStyle Libre products, for patients with type 1 diabetes, type 2 diabetes, or gestational diabetes who meet the applicable age-related labeling or supported-use and prerequisite-therapy requirements.

    CGM Medical Necessity

    CGM medical necessity

    CGM equipment is medically necessary when the requested agent meets the continuation or initial-therapy criteria.

    CGM medical necessity: The patient has type 1 diabetes, type 2 diabetes, or gestational diabetes; meets the applicable age requirement or has support for use at the patient's age; and satisfies the prerequisite-agent criterion, unless the patient qualifies for continuation therapy.

    All applicable initial-therapy elements are required.

    Required Supporting Documentation

    Documentation Required

    Submit complete clinical documentation

    Submit clinical documentation supporting CGM medical necessity and prior-authorization criteria. Include the qualifying diabetes diagnosis, age-labeling or supported-age rationale, prerequisite diabetes therapy history or exception, and continuation history when applicable.

    Documentation Required

    Document excess-quantity exceptions

    For quantities above the applicable limit, submit clinical support for the higher quantity under one of the listed quantity-limit exception pathways.

    • Support therapy with a higher dose when no maximum FDA-labeled dose applies.
    • If applicable, explain why the requested quantity cannot be achieved with a lower quantity of a higher strength within the program limit.
    Policy Summary
    PayerPrime Therapeutics
    PolicyContinuous Glucose Monitor Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionSubmit clinical documentation supporting the qualifying diabetes diagnosis, age requirement, prerequisite therapy, and continuation history when applicable.
    SourceLink
    On This Page
    Coverage CriteriaCovered Products and Quantity LimitsProvider Requirements and Denial RisksContinuous Glucose Monitor OverviewCGM Medical NecessityRequired Supporting Documentation
    Requested quantity at or below maximum FDA-labeled dose
  1. Higher dose above maximum labeled dose: The requested quantity exceeds the program limit and the requested quantity exceeds the maximum FDA-labeled dose, with support for therapy with a higher dose.Requested quantity exceeds maximum FDA-labeled dose
  2. Dexcom G6 Transmitter Quantity Limit
    ProductDexcom G6 transmitter
    EquipmentTransmitter
    Quantity-limit duration90 days
    Dexcom G7 15-Day and FreeStyle Libre 2 Plus/3 Plus Sensor Quantity Limit
    ProductsDexcom G7 15-day sensor; FreeStyle Libre 2 Plus sensor; FreeStyle Libre 3 Plus sensor
    Quantity limit2 sensors
    Duration30 days
    FreeStyle Libre 14-Day, Libre 2, and Libre 3 Sensor Quantity Limit
    ProductsFreeStyle Libre 14-day sensor; FreeStyle Libre 2 sensor; FreeStyle Libre 3 sensor
    Quantity limit2 sensors
    Duration28 days
    • Eligible prerequisite categories include alpha-glucosidase inhibitors, Cycloset (bromocriptine), DPP-4 inhibitors or combinations, glucagon, GLP-1 or GLP-1/GIP agonists, insulin, insulin/GLP-1 combinations, meglitinides, metformin or combinations, SGLT or combinations, sulfonylureas, Symlin, thiazolidinediones or combinations, and Tzield.
    Documentation Required

    Diagnosis and Age Documentation

    For an initial request, document a qualifying diabetes diagnosis and the requested CGM agent. Also document that the patient's age is within FDA labeling for the requested indication or provide support for use of the requested agent at the patient's age.

    • Qualifying diagnoses: type 1 diabetes, type 2 diabetes, or gestational diabetes.
    • Identify the requested CGM agent and the applicable age rationale.
    Documentation Required

    Continuation Therapy History

    For continuation therapy, the prescriber must state that the patient has been treated with the requested CGM agent within the past 90 days and is at risk if therapy is changed. Treatment started only with samples is not approvable.

    • All listed target agents are eligible for continuation of therapy.
    • Document ongoing risk or clinical need for continuation.
    Documentation Required

    Prerequisite-Agent Documentation

    Provide medication history or supporting clinical documentation for the prerequisite-agent requirement. The record must substantiate recent use, intolerance or hypersensitivity, or an FDA-labeled contraindication to all prerequisite agents, as applicable.

    • Recent prerequisite-agent use must be within the past 90 days.
    • For intolerance or hypersensitivity, identify the affected prerequisite agent and provide supporting documentation.
    Billing Rule

    Quantity-Limit Exception Documentation

    If the requested quantity exceeds the program quantity limit, submit documentation supporting the applicable quantity-limit exception. The request must meet one of the policy's higher-dose or quantity-conversion exception pathways.

    • No maximum FDA-labeled dose: document support for therapy with a higher dose.
    • Within the maximum FDA-labeled dose: document why the requested quantity cannot be achieved with a lower quantity of a higher strength that remains within the program limit.
    • Exceeds the maximum FDA-labeled dose: document support for therapy with a higher dose.
    Denial Risk

    Clinical Eligibility Not Established

    Coverage may be denied when the request does not establish a qualifying diagnosis, requested-agent eligibility, applicable age rationale, or the required prerequisite diabetes-therapy pathway.

    • The initial-therapy criteria require a qualifying diagnosis, appropriate age support, and one prerequisite-agent criterion.
    • An FDA-labeled contraindication must apply to all prerequisite agents to satisfy that pathway.
    Denial Risk

    Continuation Criteria Not Met

    Continuation criteria are not met when the prescriber does not document treatment with the requested agent within the past 90 days and the patient's risk if therapy is changed. Use of samples alone does not establish approvable continuation therapy.

    • The requested agent must have been used within the past 90 days.
    • Ongoing risk or need for continuation must be documented.
    Denial Risk

    Quantity Limit Exceeded Without Exception

    A quantity-limit exception is not established when the requested quantity exceeds the program limit but the submission lacks policy-supported documentation for the applicable higher-dose or quantity-conversion exception.

    • Requests exceeding the limit must satisfy one complete exception pathway.
    • Absent supporting documentation, excess quantities remain subject to denial.